Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: The 30-month event-free and overall survival rates for patients with HER2 overexpression treated with chemotherapy and trastuzumab were 32% and 59%, respectively. For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 50%, respectively. There was no clinically significant short-term cardiotoxicity in patients treated with trastuzumab and doxorubicin. CONCLUSION: Despite intensive chemotherapy plus trastuzumab for patients with HER2-positive disease, the outcome for all patients was poor, with no significant difference between the HER2-positive and HER2-negative groups. Although our findings suggest that trastuzumab can be safely delivered in combination with anthracycline-based chemotherapy and dexrazoxane, its therapeutic benefit remains uncertain. Definitive assessment of trastuzumab's potential role in treating osteosarcoma would require a randomized study of patients with HER2-positive disease.
|
Authors | David Ebb, Paul Meyers, Holcombe Grier, Mark Bernstein, Richard Gorlick, Steven E Lipshultz, Mark Krailo, Meenakshi Devidas, Donald A Barkauskas, Gene P Siegal, William Shay Ferguson, George Douglas Letson, Karen Marcus, Allen Goorin, Peter Beardsley, Neyssa Marina |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 30
Issue 20
Pg. 2545-51
(Jul 10 2012)
ISSN: 1527-7755 [Electronic] United States |
PMID | 22665540
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Receptor, ErbB-2
- Trastuzumab
|
Topics |
- Adolescent
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bone Neoplasms
(drug therapy, metabolism, mortality, pathology)
- Female
- Humans
- Male
- Neoplasm Metastasis
- Osteosarcoma
(drug therapy, metabolism, mortality, pathology)
- Receptor, ErbB-2
(metabolism)
- Trastuzumab
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|